Search Results - "YAMADA, Ren"

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B by Suzuki, Kazuharu, Suda, Goki, Yamamoto, Yoshiya, Abiko, Satoshi, Kinoshita, Kenji, Miyamoto, Shuichi, Sugiura, Ryo, Kimura, Megumi, Maehara, Osamu, Yamada, Ren, Kitagataya, Takashi, Shigesawa, Taku, Ohara, Masatsugu, Kawagishi, Naoki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Sakamoto, Naoya

“…For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent…”
Get full text

Tenofovir–disoproxil–fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection by Suzuki, Kazuharu, Suda, Goki, Yamamoto, Yoshiya, Furuya, Ken, Baba, Masaru, Nakamura, Akinobu, Miyoshi, Hideaki, Kimura, Megumi, Maehara, Osamu, Yamada, Ren, Kitagataya, Takashi, Yamamoto, Koji, Shigesawa, Taku, Nakamura, Akihisa, Ohara, Masatsugu, Kawagishi, Naoki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Ohnishi, Shunsuke, Sakamoto, Naoya

“…Background Entecavir and tenofovir–disoproxil–fumarate are first-line nucleos(t)ide analogs (NA) for treatment of hepatitis B virus (HBV) infections; however,…”
Get full text

Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy‐associated hepatitis in Japan by Kitagataya, Takashi, Suda, Goki, Nagashima, Kazunori, Katsurada, Takehiko, Yamamoto, Koji, Kimura, Megumi, Maehara, Osamu, Yamada, Ren, Shigesawa, Taku, Suzuki, Kazuharu, Nakamura, Akihisa, Ohara, Masatsugu, Umemura, Machiko, Kawagishi, Naoki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Ohnishi, Shunsuke, Komatsu, Yoshito, Hata, Hiroo, Takeuchi, Satoshi, Abe, Takashige, Sakakibara‐Konishi, Jun, Teshima, Takanori, Homma, Akihiro, Sakamoto, Naoya

“…Background and Aim Immune checkpoint inhibitors (ICI) have revolutionized anti‐malignancy therapy and thus have been increasingly used. Although ICI may cause…”
Get full text

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients by Nakai, Masato, Suda, Goki, Ogawa, Koji, Yoshida, Sonoe, Hosoda, Shunichi, Kubo, Akinori, Tokuchi, Yoshimasa, Kitagataya, Takashi, Yamada, Ren, Shigesawa, Taku, Ohara, Masatsugu, Sho, Takuya, Morikawa, Kenichi, Sakamoto, Naoya

“…Covert hepatic encephalopathy (CHE) impairs patient quality of life and occurs in approximately 30% of liver cirrhosis (LC) cases. Japanese clinical practice…”
Get full text

Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis by Nakai, Masato, Morikawa, Kenichi, Sasaki, Takashi, Kohya, Risako, Yoshida, Sonoe, Hosoda, Shunichi, Kubo, Akinori, Tokuchi, Yoshimasa, Kitagataya, Takashi, Yamada, Ren, Ohara, Masatsugu, Sho, Takuya, Suda, Goki, Ogawa, Koji, Sakamoto, Naoya

“…Background Acute kidney injury (AKI) is associated with liver cirrhosis (LC), water retention, diuretics to treat water retention, and a poor prognosis…”
Get full text

HSP DNAJB8 Controls Tumor-Initiating Ability in Renal Cancer Stem―like Cells by NISHIZAWA, Satoshi, HIROHASHI, Yoshihiko, SOKOLOVSKAYA, Alice, MATSUZAKI, Junichi, YAMADA, Ren, FUJII, Reona, KAMPINGA, Harm H, KONDO, Toru, HASEGAWA, Tadashi, HARA, Isao, SATO, Noriyuki, TORIGOE, Toshihiko, TAKAHASHI, Akari, TAMURA, Yasuaki, MORI, Takashi, KANASEKI, Takayuki, KAMIGUCHI, Kenjiro, ASANUMA, Hiroko, MORITA, Rena

“…Cancer stem-like cells (CSC) are a small population of cancer cells with superior tumor initiating, self-renewal, and differentiation properties. In this…”
Get full text

Durable response without recurrence to Tolvaptan improves long-term survival by Nakai, Masato, Suda, Goki, Kubo, Akinori, Tokuchi, Yoshimasa, Kitagataya, Takashi, Yamada, Ren, Shigesawa, Taku, Suzuki, Kazuharu, Nakamura, Akihisa, Kawagishi, Naoki, Ohara, Masatsugu, Umemura, Machiko, Sho, Takuya, Morikawa, Kenichi, Ogawa, Koji, Sakamoto, Naoya

“…Background Decompensated liver cirrhosis patients with refractory ascites or pleural effusion have a poor prognosis. Tolvaptan has been used for treating water…”
Get full text

The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease by Nakamura, Akihisa, Yamamoto, Koji, Takeda, Rei, Yamada, Ren, Kubo, Akinori, Morikawa, Kenichi, Ando, Sayaka, Shimazaki, Tomoe, Izumi, Takaaki, Umemura, Machiko, Kitagataya, Takashi, Shigesawa, Taku, Suzuki, Kazuharu, Kimura, Megumi, Nakai, Masato, Sho, Takuya, Suda, Goki, Natsuizaka, Mitsuteru, Ogawa, Koji, Ohnishi, Shunsuke, Sugiyama, Toshiro, Takeda, Hiroshi, Sakamoto, Naoya

“…Background and Aims Although various noninvasive markers and prediction formulas for nonalcoholic steatohepatitis (NASH) have been reported, they are of value…”
Get full text

Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria by Sho, Takuya, Suda, Goki, Ogawa, Koji, Kimura, Megumi, Kubo, Akinori, Tokuchi, Yoshimasa, Kitagataya, Takashi, Maehara, Osamu, Ohnishi, Shunsuke, Shigesawa, Taku, Nakamura, Akihisa, Yamada, Ren, Ohara, Masatsugu, Kawagishi, Naoki, Natsuizaka, Mitsuteru, Nakai, Masato, Morikawa, Kenichi, Furuya, Ken, Baba, Masaru, Yamamoto, Yoshiya, Suzuki, Kazuharu, Izumi, Takaaki, Meguro, Takashi, Terashita, Katsumi, Ito, Jun, Miyagishima, Takuto, Sakamoto, Naoya

“…Aim A clinical trial (IMbrave150) indicated the efficacy and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma…”
Get full text

Time‐dependent changes in the seroprevalence of COVID‐19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID‐19 by Suda, Goki, Ogawa, Koji, Kimura, Megumi, Maehara, Osamu, Kitagataya, Takashi, Ohara, Masatsugu, Tokuchi, Yoshimasa, Kubo, Akinori, Yamada, Ren, Shigesawa, Taku, Suzuki, Kazuharu, Kawagishi, Naoki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Sakamoto, Naoya

“…Aim Coronavirus disease 2019 (COVID‐19) is a serious public health concern, with unclarified prevalence in Japan. Concomitant liver disease could increase the…”
Get full text

Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication by Nakai, Masato, Yamamoto, Yoshiya, Baba, Masaru, Suda, Goki, Kubo, Akinori, Tokuchi, Yoshimasa, Kitagataya, Takashi, Yamada, Ren, Shigesawa, Taku, Suzuki, Kazuharu, Nakamura, Akihisa, Sho, Takuya, Morikawa, Kenichi, Ogawa, Koji, Furuya, Ken, Sakamoto, Naoya

“…Liver stiffness measurement (LSM) is a useful tool for assessing advanced liver fibrosis, an important risk factor for hepatocellular carcinoma (HCC) following…”
Get full text

Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma by Shigesawa, Taku, Suda, Goki, Kimura, Megumi, Maehara, Osamu, Tokuchi, Yoshimasa, Kubo, Akinori, Yamada, Ren, Furuya, Ken, Baba, Masaru, Kitagataya, Takashi, Suzuki, Kazuharu, Ohara, Masatsugu, Kawagishi, Naoki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Sakamoto, Naoya

“…A deteriorated liver functional reserve during systemic therapy for unresectable hepatocellular carcinoma (HCC) causes poor patient outcomes. We aimed to…”
Get full text

Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis by Suda, Goki, Baba, Masaru, Yamamoto, Yoshiya, Sho, Takuya, Ogawa, Koji, Kimura, Megumi, Hosoda, Shunichi, Yoshida, Sonoe, Kubo, Akinori, Fu, Qingjie, Yang, Zijian, Tokuchi, Yoshimasa, Kitagataya, Takashi, Maehara, Osamu, Ohnishi, Shunsuke, Yamada, Ren, Ohara, Masatsugu, Kawagishi, Naoki, Natsuizaka, Mitsuteru, Nakai, Masato, Morikawa, Kenichi, Furuya, Ken, Suzuki, Kazuharu, Izumi, Takaaki, Meguro, Takashi, Terashita, Katsumi, Ito, Jun, Kobayashi, Tomoe, Tsunematsu, Izumi, Sakamoto, Naoya

“…No prospective study on the efficacy of tenofovir alafenamide (TAF), a novel tenofovir prodrug, in preventing hepatitis B virus (HBV) reactivation has yet been…”
Get full text

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C by Kawagishi, Naoki, Suda, Goki, Kimura, Megumi, Maehara, Osamu, Yamada, Ren, Tokuchi, Yoshimasa, Kubo, Akinori, Kitagataya, Takashi, Shigesawa, Taku, Suzuki, Kazuharu, Ohara, Masatsugu, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Kudo, Yusuke, Nishida, Mutsumi, Sakamoto, Naoya

“…We previously revealed that Angiopoietin-2 (Ang2) predicts non-regression of liver fibrosis based on liver stiffness measurement (LSM) at 24 weeks after…”
Get full text

High serum angiopoietin‐2 level predicts non‐regression of liver stiffness measurement‐based liver fibrosis stage after direct‐acting antiviral therapy for hepatitis C by Kawagishi, Naoki, Suda, Goki, Kimura, Megumi, Maehara, Osamu, Shimazaki, Tomoe, Yamada, Ren, Kitagataya, Takashi, Shigesawa, Taku, Suzuki, Kazuharu, Nakamura, Akihisa, Ohara, Masatsugu, Umemura, Machiko, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Kudo, Yusuke, Nishida, Mutsumi, Sakamoto, Naoya

“…Aim Factors associated with improvement of liver fibrosis after successful hepatitis C virus (HCV) eradication by interferon (IFN)‐free direct‐acting antiviral…”
Get full text

Glucagon-like peptide-1 production in the GLUTag cell line is impaired by free fatty acids via endoplasmic reticulum stress by Hayashi, Hiroto, Yamada, Ren, Das, Siddhartha Shankar, Sato, Taiki, Takahashi, Aki, Hiratsuka, Masahiro, Hirasawa, Noriyasu

“…Abstract Objects Glucagon-like peptide-1 (GLP-1) is secreted from intestinal L cells, enhances glucose-stimulated insulin secretion, and protects pancreas beta…”
Get full text

Overestimated renal function in patients with liver cirrhosis predicts poor prognosis by Yoshida, Sonoe, Suda, Goki, Ohara, Masatsugu, Kimura, Megumi, Yang, Zijian, Maehara, Osamu, Fu, Qingjie, Hosoda, Shunichi, Akinori, Kubo, Tokuchi, Yoshimasa, Yamada, Ren, Kitagataya, Takashi, Suzuki, Kazuharu, Kawagishi, Naoki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Ohnishi, Shunsuke, Sakamoto, Naoya

“…Aim A high prevalence of overestimated renal function in patients with liver cirrhosis (LC) has been reported; nonetheless, its impact on prognosis remains…”
Get full text

Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals by Tokuchi, Yoshimasa, Suda, Goki, Kimura, Megumi, Maehara, Osamu, Kitagataya, Takashi, Kubo, Akinori, Yoshida, Sonoe, Fu, Qingjie, Yang, Zijian, Hosoda, Shunichi, Ohara, Masatsugu, Yamada, Ren, Suzuki, Kazuharu, Kawagishi, Naoki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Ohnishi, Shunsuke, Sakamoto, Naoya

“…We aimed to evaluate factors associated with changes in skeletal muscle mass in hepatitis C virus (HCV)-infected patients after treatment with direct-acting…”
Get full text

Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients by Umemura, Machiko, Ogawa, Koji, Morikawa, Kenichi, Kubo, Akinori, Tokuchi, Yoshimasa, Yamada, Ren, Kitagataya, Takashi, Shigesawa, Taku, Shimazaki, Tomoe, Kimura, Megumi, Suzuki, Kazuharu, Nakamura, Akihisa, Ohara, Masatsugu, Kawagishi, Naoki, Izumi, Takaaki, Nakai, Masato, Sho, Takuya, Suda, Goki, Natsuizaka, Mitsuteru, Ono, Kota, Murata, Kazumoto, Sugiyama, Masaya, Mizokami, Masashi, Sakamoto, Naoya

“…Background & Aims Benefits of nucleos(t)ide analogs (NAs) on hepatitis B surface antigen (HBsAg) reduction and interferon‐lambda3 (IFN‐λ3) induction are still…”
Get full text

Case Report: Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Presenting With Liver Cirrhosis and Steroid-Responsive Interstitial Pneumonia by Takimoto-Sato, Michiko, Miyauchi, Toshinari, Suzuki, Masaru, Ujiie, Hideyuki, Nomura, Toshifumi, Ikari, Tomoo, Nakamura, Tomohiko, Takahashi, Kei, Matsumoto-Sasaki, Machiko, Kimura, Hirokazu, Kimura, Hiroki, Matsui, Yuichiro, Kitagataya, Takashi, Yamada, Ren, Suzuki, Kazuharu, Nakamura, Akihisa, Nakai, Masato, Sho, Takuya, Ogawa, Koji, Sakamoto, Naoya, Yamaguchi, Naoko, Otsuka, Noriyuki, Tomaru, Utano, Konno, Satoshi

“…Hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis (POIKTMP) is an extremely rare disease caused by mutations in…”
Get full text